Press Release Archives - Page 21 of 22

Spectral Announces Voting Results of Annual General and Special Meeting and Promotion of Chris Seto to Chief Operating Officer

TORONTO, Canada –June 5, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that, at the annual general and special meeting (the “Meeting”)...

Spectral Medical Inc. Announces Proposed Public Offering of Units

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario | May 27, 2020 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for...

Spectral Announces First Quarter Results

TORONTO, Canada – May 15, 2020 – Spectral Medical Inc., (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2020. Financial Review Revenue...

Spectral Medical Provides Corporate Update

The Company remains well positioned with financial strength COVID-19 patients using PMX in the U.S. showing positive signs in recovery SAMI used successfully for CRRT in COVID-19 patients Toronto, Ontario | April 28, 2020 – Spectral Medical Inc. (“Spectral” or the...

Health Canada Issues an Interim Order for Spectral Medical’s PMX to Treat COVID-19 Patients

PMX has successfully been used for treatment in COVID-19 patients in the U.S., Japan and Italy Interim Order expands already approved PMX Health Canada indications for use to include treatment of COVID-19 patients Toronto, Ontario | April 20, 2019 – Spectral...

US FDA Approves an Investigational Device Exemption for Spectral Medical PMX to Treat COVID-19 Patients Suffering from Septic Shock

PMX has successfully been used for treatment in COVID-19 patients in the U.S., Japan and Italy IDE approval provides access to PMX to help clinicians treat COVID-19 patients in septic shock Publications have demonstrated endotoxin removal by PMX can decrease cytokine...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.